BioSpace News Archive

Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 912,858 shares of its common stock at a purchase price of $10.50 per share for total gross proceeds of approximately $9.59 million, before deducting placement agent fees and offering expenses.

HIV/AIDS advocates will join together in Fort Lauderdale on January 6-7, 2020 for the 2nd Ryan White Clinics for 340B’s national conference.

Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 952,383 shares of its common stock

BeiGene, Ltd. announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration as a treatment for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies.